Immunodiagnostic Systems Holdings has reached agreement with Technogenetics srl to enable IDS to sell TGS's range of assay kits under the IDS brand, on a global basis.
TGS produces a broad range of CE approved CLIA automated assay kits for use in the fields of autoimmune and infectious disease diagnostics, which have been developed for the IDS iSYS analyser.
IDS said this agreement followed a more restricted arrangement where it sold a limited number of the TGS assays in a small number of European countries.
The new agreement, which runs for an initial period of ten years, gives IDS the right, subject to obtaining the necessary regulatory approvals, to sell the kits under the IDS brand on a worldwide basis.
At 8:24am: (LON:IDH) Immunodiagnostic Systems Holdings PLC share price was +10p at 290p